Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02329366 · ClinicalTrials.gov registry record
Development of a Cellular Biomarker for the Diagnosis and Treatment of Diabetic Foot Ulcers
A clinical trial, sponsored by Winthrop University Hospital.
- Completed
- Registry status
- 30
- Enrollment target
NCT02329366: Completed study, sponsored by Winthrop University Hospital.
NCT02329366 is a clinical trial that has completed, run by Winthrop University Hospital. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02329366 has completed, sponsored by Winthrop University Hospital.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This project aims to result in the identification of such markers, and the development of a feasible quantitative method of distinguishing between tissue that has the capacity to heal and tissue that does not, thus identifying a non-healing phenotype.
Interventions
- OTHER Specimen Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-12 |
| Est. Completion | 2020-12-01 |
What the finished NCT02329366 record still lists
NCT02329366 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Specimen Collection is the first listed.
NCT02329366 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02329366 about?
NCT02329366 is a clinical study titled "Development of a Cellular Biomarker for the Diagnosis and Treatment of Diabetic Foot Ulcers". This project aims to result in the identification of such markers, and the development of a feasible quantitative method of distinguishing between tissue that has the capacity to heal and tissue that does not, thus identifying a non-healing phenotype.
What is the current status of trial NCT02329366?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2014-12. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT02329366?
The interventions under investigation include: Specimen Collection (OTHER).
Who is sponsoring clinical trial NCT02329366?
This trial is sponsored by Winthrop University Hospital, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia